KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Halozyme Therapeutics (HALO) over the last 2 years, with Mar 2011 value amounting to $80.9 million.

  • Halozyme Therapeutics' Cash & Equivalents rose 171.95% to $419.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $419.7 million, marking a year-over-year increase of 171.95%. This contributed to the annual value of $115.8 million for FY2024, which is 2.13% down from last year.
  • Halozyme Therapeutics' Cash & Equivalents amounted to $419.7 million in Q3 2025, which was up 578.40% from $61.9 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Cash & Equivalents high stood at $499.4 million for Q1 2021, and its period low was $61.9 million during Q2 2025.
  • In the last 3 years, Halozyme Therapeutics' Cash & Equivalents had a median value of $164.6 million in 2024 and averaged $181.0 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Revenue - Interest and Investment Income tumbled by 46.53% in 2010, and later rose by 24.20% in 2011.
  • Over the past 3 years, Halozyme Therapeutics' Revenue - Interest and Investment Income (Quarterly) stood at $77.1 million in 2009, then increased by 18.40% to $91.3 million in 2010, then increased by 24.20% to $80.9 million in 2011.
  • Its last three reported values are $419.7 million in Q3 2025, $61.9 million for Q2 2025, and $176.3 million during Q1 2025.